New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Core Insights - Castle Biosciences is presenting new research at the AACR Annual Meeting 2025 aimed at improving care for patients with cutaneous and uveal melanoma through innovative testing [1][2] Group 1: Research Presentations - Castle Biosciences will present findings on DecisionDx-Melanoma, which identifies early-stage cutaneous melanoma patients at higher risk of developing distant metastases, showing significant differences in metastasis rates between risk classes [5][6] - The study on DecisionDx-UM aims to develop a minimally invasive aqueous proteomic signature to assess the malignant potential of small uveal melanocytic tumors, addressing the need for effective monitoring without repeated biopsies [5][6] Group 2: Product Information - DecisionDx-Melanoma is a 31-gene expression profile test that informs on a patient's risk of sentinel lymph node positivity and melanoma recurrence, with over 191,000 tests ordered since its introduction [7] - DecisionDx-UM is a 15-gene expression profile test that predicts metastasis risk in uveal melanoma patients and is widely used in ocular oncology practices across the United States [8] Group 3: Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [9][10]